Expects to Commence Phase 2a of CAReS During the First Quarter of 2023SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE)...
NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that this year’s first...
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging...
REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology...
Focal One® HIFU treatment resulted in significant improvements in endometriosis symptoms and quality of life (QoL)Positive safety profile with 96.7% of...
First endocrine innovation in more than 20 years which has shown improved efficacy over standard-of-care treatments in patients with advanced breast...
TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage...
Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such...
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader...
NEW YORK, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for...
Cash Receipts Q2 2022 to Year to DateMELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”...
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
HAMILTON, BERMUDA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Process for divestiture / partnering of legacy assets continuesStrong data from Bentrio®...
Preclinical data show synergistic activity for the targeted protein degrader SP-3164 with rituximab in non-Hodgkin’s lymphomas, and significantly better performance...
– R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing...
MINNEAPOLIS, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela” or the “Company”), a clinical stage company...